TCRX — Tscan Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.21m
- -$54.17m
- $10.33m
Brief: TScan Therapeutics Reports Third Quarter 2021 Financial Results
Brief: Tscan Therapeutics Appoints Zoran Zdraveski As Chief Legal Officer
TScan Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: TScan Therapeutics Reports Q2 Loss Per Share Of $7.69
Brief: Tscan Therapeutics To Present Discovery Of T Cell Targets For Covid-19 At The Cell-Mediated Therapies For Infectious Disease Summit
TScan Therapeutics slides in market debut
NASDAQ RESUMED AT 12:07 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:56 AM
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:42 AM
NASDAQ RESUMED AT 09:42 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:33 AM
NASDAQ RESUMED AT 09:34 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:01 AM